Published in
IMA - Press, Modern Rheumatology Journal, 3(18), p. 134-139, 2024
DOI: 10.14412/1996-7012-2024-3-134-139
Links
Tools
Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”
,
V. I. Mazurov ,
E. L. Nasonov ,
S. A. Lukyanov ,
T. V. Dubinina ,
I. Z. Gaidukova ,
A. A. Klimenko ,
S. A. Lapshina ,
G. V. Lukina ,
M. A. Korolev ,
R. O. Dreval ,
P. I. Pchelnikova,
N. V. Shatalova
Full text: Download
Abstract
On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.